Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer

Li, Lan; Cao, Jianhua; Chen, Chunyan; Qin, Yaqian; He, Licai; Gu, Haihua; Wu, Guang

doi:10.1016/j.heliyon.2023.e15164

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ADCs including naturally-derived agents that are tested in clinical trials in endocrine-independent HER-2-negative BC are presented in the next chapter. For pre-clinical setting a good example is ADC consisting of humanized MUC1 antibody linked to monomethyl auristatin (MMAE) and showing activity in cell line model ( Li et al, 2023 ). MMAE is an antimitotic agent derived from sea hare ( Dolabella auricularia [Lightfoot], 1786) from Aplysiidae that is too toxic to be used on its own, but linking to mAb allows toxicity to be limited ( Püsküllüoğlu and Michalak, 2022 ).…”

Section: Advancing Drug Delivery: Novel Technologiesmentioning

confidence: 99%

The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer

Püsküllüoğlu,

Michalak

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Breast cancer (BC) is a heterogenous disease, with prognosis and treatment options depending on Estrogen, Progesterone receptor, and Human Epidermal Growth Factor Receptor-2 (HER-2) status. HER-2 negative, endocrine-independent BC presents a significant clinical challenge with limited treatment options. To date, promising strategies like immune checkpoint inhibitors have not yielded breakthroughs in patient prognosis. Despite being considered archaic, agents derived from natural sources, mainly plants, remain backbone of current treatment. In this context, we critically analyze novel naturally-derived drug candidates, elucidate their intricate mechanisms of action, and evaluate their pre-clinical in vitro and in vivo activity in endocrine-independent HER-2 negative BC. Since pre-clinical research success often does not directly correlate with drug approval, we focus on ongoing clinical trials to uncover current trends. Finally, we demonstrate the potential of combining cutting-edge technologies, such as antibody-drug conjugates or nanomedicine, with naturally-derived agents, offering new opportunities that utilize both traditional cytotoxic agents and new metabolites.

show abstract

Section: Advancing Drug Delivery: Novel Technologiesmentioning

confidence: 99%